Zenas Biopharma, Common Etf Performance
| ZBIO Etf | USD 10.44 2.01 16.14% |
The entity maintains a market beta of 0.86, which attests to possible diversification benefits within a given portfolio. Zenas BioPharma, returns are very sensitive to returns on the market. As the market goes up or down, Zenas BioPharma, is expected to follow.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the ETF investors. ...more
1 | Zenas BioPharma director acquires 999k in company stock | 09/17/2024 |
2 | Zenas started at buy by four banks on lead drug potential | 10/08/2024 |
3 | Acquisition by Moulder Leon O Jr of 7500 shares of Zenas BioPharma, at 15.0 subject to Rule 16b-3 | 11/18/2024 |
4 | Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3 | 11/19/2024 |
| Begin Period Cash Flow | 67.3 M | |
| End Period Cash Flow | 56.9 M |
Zenas |
Zenas BioPharma, Relative Risk vs. Return Landscape
If you would invest 1,815 in Zenas BioPharma, Common on August 24, 2024 and sell it today you would lose (771.00) from holding Zenas BioPharma, Common or give up 42.48% of portfolio value over 90 days. Zenas BioPharma, Common is currently does not generate positive expected returns and assumes 5.811% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of etfs are less volatile than Zenas, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zenas BioPharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zenas BioPharma,'s investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as Zenas BioPharma, Common, and traders can use it to determine the average amount a Zenas BioPharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.16
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZBIO |
Estimated Market Risk
| 5.81 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.93 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zenas BioPharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zenas BioPharma, by adding Zenas BioPharma, to a well-diversified portfolio.
Zenas BioPharma, Fundamentals Growth
Zenas Etf prices reflect investors' perceptions of the future prospects and financial health of Zenas BioPharma,, and Zenas BioPharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zenas Etf performance.
| EBITDA | (56.31 M) | ||||
| Total Debt | 293.9 M | ||||
| Book Value Per Share | (21.07) X | ||||
| Cash Flow From Operations | (30.53 M) | ||||
| Earnings Per Share | (3.90) X | ||||
| Total Asset | 68.18 M | ||||
| Retained Earnings | (230.4 M) | ||||
About Zenas BioPharma, Performance
By examining Zenas BioPharma,'s fundamental ratios, stakeholders can obtain critical insights into Zenas BioPharma,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zenas BioPharma, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.| Zenas BioPharma, generated a negative expected return over the last 90 days | |
| Zenas BioPharma, has high historical volatility and very poor performance | |
| Zenas BioPharma, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (37.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| The fund created three year return of -33.0% | |
| Latest headline from MacroaxisInsider: Acquisition by Moulder Leon O Jr of 2500 shares of Zenas BioPharma, at 14.57 subject to Rule 16b-3 | |
| Zenas BioPharma, Common keeps most of the net assets in exotic instruments. |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.